Answers are grounded in this paper and cite their sources.
Background In a placebo-controlled trial of the peptide-based therapeutic HIV-1 p24 Gag vaccine candidate Vacc-4x, participants on combination antiretroviral therapy (cART) received six immunizations over 18weeks, followed by analytical treatment interruption (ATI) between weeks 28 and 52. Cell-mediated immune responses were investigated as predictors of Vacc-4x effect (VE) on viral load (VL) and CD4 count during ATI. Methods All analyses of week 28 responses and fold-changes relative to baseline considered per-protocol participants (Vacc-4x:placebo=72:32) resuming cART after week 40. Linear regression models with interaction tests were used. VE was estimated as the Vacc-4x–placebo difference in log 10 -transformed VL (VE VL ) or CD4 count (VE CD4 ). Findings A lower fold-change of CD4+ T-cell proliferation was associated with VE CD4 at week 48 ( p =0.036, multiplicity adjusted q=0.036) and week 52 ( p =0.040, q=0.080). A higher fold-change of IFN-γ in proliferation supernatants was associated with VE VL at week 44 ( p =0.047, q=0.07). A higher fold-change of TNF-α was associated with VE VL at week 44 ( p =0.045, q=0.070), week 48 ( p =0.028, q=0.070), and week 52 ( p =0.037, q=0.074). A higher fold-change of IL-6 was associated with VE VL at week 48 ( p =0.017, q=0.036). TNF-α levels (>median) were associated with VE CD4 at week 48 ( p =0.009, q=0.009). Interpretation These exploratory analyses highlight the potential value of investigating biomarkers in T-cell proliferation supernatants for VE in clinical studies.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: